News Release


Kyorin and Esai Form an Alliance on Marketing of "rizatriptan benzoate" (generic name), an agent for migraine

February 26, 2003

On February 26, Kyorin Pharmaceutical Co., Ltd. ("Kyorin", Head office: Tokyo, President: Ikuo Ogihara) and Eisai Co., Ltd. ("Eisai", Head office: Tokyo, President: Haruo Naito) have signed an agreement for jointly marketing an agent for migraine treatment, "rizatriptan benzoate" (Maxalt : brand name in overseas), the finished product of which Kyorin has applied for the import approval in Japan.

Get Adobe Acrobat Reader

Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.